Future Treatment for Anemia of LR-MDS

Opinion
Video

An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.

Video content above is prompted by the following:

  • What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?
    • What are the current unmet needs in the treatment of anemia in LR-MDS?

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
Related Content
Immunotherapy Advances and Challenges in T-Cell Lymphoma

Immunotherapy Advances and Challenges in T-Cell Lymphoma

Jordyn Sava
July 14th 2025
Article

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

Read More

Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Targeted Oncology Staff
July 7th 2025
Article

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Read More

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Jordyn Sava
July 4th 2025
Article

Read More

Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL

Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL

Martina Canichella, MD, PhD;Elisabetta Abruzzese, MD, PhD
June 27th 2025
Article

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.

Read More

Luspatercept Outperforms ESA in Duration of Anemia Response in MDS

Luspatercept Outperforms ESA in Duration of Anemia Response in MDS

Targeted Oncology Staff
June 24th 2025
Article

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

Read More

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

Jordyn Sava
June 19th 2025
Article

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

Read More